Full Analysis capability
Thin Film Coating Lab
Cas No.: 23541-50-6
10-[(3-Amino-2,3,6-trideoxy-indole-L-lysylpyranyl)oxy]-7,8,9,10-tetrahydro-6,8,11- Hydrochloride of trihydroxy-8-acetyl-1-methoxy-5,12-naphthalenedione (8S-10S)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy -ɑ-L-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
Orange-red crystalline powder; hygroscopic
Shade, seal and store in a cool dry place.
1, acute granulocyte leukemia: whether it is a single use of daunorubicin or combined with other anti-tumor drugs, daunorubicin is suitable for the treatment of the various stages of the disease. Also used to treat promyelocytic leukemia.
2, acute lymphocytic leukemia: treatment of the disease with daunorubicin, the remission rate is very high, but due to its side effects and other effective treatments, daunorubicin is only suitable for those who have developed resistance to other drugs Case of medicine. The combination of daunorubicin, prednisone and vincristine in the acute phase of acute effusion has proven to be very successful.
3, other tumors: daunorubicin has been observed to have a good effect on neuroblastoma and rhabdomyosarcoma.